Shares of Aquestive Therapeutics fell more than 40% on January 9, 2026, after the company disclosed that the FDA identified deficiencies in its new drug application for Anaphylm, raising the risk of delayed approval. Block & Leviton is investigating the company's prior disclosures.
Contact our attorneys for a no-cost case evaluation.